Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer.
Our mission is to develop a new drug to treat Glioblastoma Multiforme.
We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.
Location: Norway, Oslo
Member count: 1-10
Total raised: $14.210719M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Meneldor | meneldor.n... |
Funding Rounds 3
| Date | Series | Amount | Investors | Deal News |
| 24.11.2022 | Series A | $3.026587M | - | finsmes.co... |
| 19.10.2022 | - | $9.784132M | - | finsmes.co... |
| 06.05.2022 | Seed | $1.4M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 24.11.2022 | Hemispheri... | Hemispherian, an Oslo, Norway-... | Norway | - | finsmes.co... |
| 19.10.2022 | Hemispheri... | Hemispherian, an Oslo, Norway-... | Norway | - | finsmes.co... |
| 06.05.2022 | Hemispheri... | Hemispherian AS, a Oslo, Norwa... | Norway | - | finsmes.co... |